Live updates from the fifth day of the AACR Annual Meeting 2026, including a plenary on early-onset cancers, the...
Guest Post by Adam Marcus, PhD Winship Cancer Institute of Emory University
Cancer immunotherapy, which entered 2014 with the accolade of Science magazine’s Breakthrough of the Year for 2013, ended the...
A new documentary, produced by Ken Burns and based on the Pulitzer Prize-winning book The Emperor of All Maladies:...
Check out the 10 blog posts from 2014 that attracted the most attention. They cover a lot of ground,...
Just before the holidays, the U.S. Food and Drug Administration (FDA) had good news for the ovarian cancer research...
Guest Post by Anees B. Chagpar, MD, MPH, MBA Yale Cancer Center
Last week, the U.S. Food and Drug Administration (FDA) announced the approval of a new vaccine—Gardasil 9—that prevents infection...
As 2014 draws to a close, we look back on an exciting year during which we provided more than...
Earlier this month we witnessed another leap forward for immunotherapy when the FDA approved blinatumomab (Blincyto) for the treatment...
Adding the PI3-kinase inhibitor pictilisib to fulvestrant doubled progression-free survival for some women with advanced hormone-receptor positive breast cancer,...